Nov 3, 8:30 PM ET
Bio-Techne's board declared a $0.08 per share cash dividend for the quarter ended September 30, 2026. The payment is conditional on the pending transaction with Merck KGaA, Darmstadt, Germany not closing on or before the November 13, 2026 record date, so the dividend tie-in to that deal matters to shareholders.
- Dividend of $0.08 per share for the quarter ended September 30, 2026
- Payable November 23, 2026 to common shareholders of record at close of business November 13, 2026
- Dividend applies only if the Merck KGaA transaction has not closed on or before November 13, 2026
- Future dividends will be considered by the Board on a quarterly basis
Read the filing on SEC.gov ↗
Aug 12, 6:30 AM ET
Bio-Techne reported fourth-quarter fiscal 2026 revenue of $321.2 million, up 1% as reported and 3% organic, with GAAP EPS of $0.35 versus a loss of $0.11 a year earlier. Adjusted EPS was $0.52, down from $0.53, and full-year adjusted EPS rose to $1.93 from $1.92 on flat revenue of $1.2 billion. The company said it will no longer hold quarterly investor calls because of its pending acquisition by Merck KGaA, Darmstadt, Germany, at $73 per share in cash.
- Q4 fiscal 2026 net sales were $321.2 million, up 1% reported and 3% organic.
- Q4 GAAP EPS was $0.35 versus $(0.11) a year earlier; adjusted EPS was $0.52 versus $0.53.
- Full-year fiscal 2026 net sales were flat at $1.2 billion; full-year adjusted EPS was $1.93 versus $1.92.
- Board declared an $0.08 per share dividend, payable September 4, 2026, to holders of record on August 24, 2026.
Read the filing on SEC.gov ↗
Jun 25, 6:49 PM ET
Bio-Techne entered a merger agreement under which Merck KGaA's subsidiary will merge into the company, leaving Bio-Techne as a wholly-owned Merck KGaA subsidiary. Each share will convert into the right to receive $73.00 in cash, and the board has recommended that shareholders approve the deal.
- Merger consideration: $73.00 in cash per share of common stock, less any required tax withholdings
- Buyer: Merck KGaA, Darmstadt, Germany, through its subsidiary EMD Holdings NewCo, Inc.
- Closing requires majority shareholder approval, expiration of the Hart-Scott-Rodino waiting period and other required approvals, and no Burdensome Condition
Read the filing on SEC.gov ↗
May 6, 6:30 AM ET
Bio-Techne reported third-quarter fiscal 2026 results for the quarter ended March 31, 2026, with net sales down 2% to $311.4 million. GAAP diluted EPS rose to $0.32 from $0.14, but adjusted diluted EPS fell to $0.53 from $0.56, and the company said demand from biotech customers has not yet broadly recovered. The company also declared a quarterly dividend of $0.08 per share.
- Net sales fell 2% to $311.4 million; organic revenue also fell 2%, with foreign exchange adding 2%.
- GAAP diluted EPS was $0.32 versus $0.14; GAAP operating income rose 95% to $75.5 million.
- Adjusted diluted EPS was $0.53 versus $0.56, and adjusted operating margin was 34.2% versus 34.9%.
- Dividend of $0.08 per share is payable May 29, 2026, to shareholders of record on May 18, 2026.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
